Pharmacology, Toxicology and Pharmaceutical Science
Castration Resistant Prostate Cancer
100%
Prostate Cancer
97%
Cabazitaxel
81%
Docetaxel
61%
Androgen Receptor
58%
Pembrolizumab
53%
Overall Survival
53%
Enzalutamide
50%
Chemotherapy
48%
Abiraterone
40%
Androgen
38%
Neoplasm
32%
Diseases
32%
Transitional Cell Carcinoma
29%
Pharmacokinetics
22%
Malignant Neoplasm
21%
Darolutamide
17%
Progression Free Survival
17%
Monotherapy
16%
Aneuploidy
15%
Taxane
14%
Biological Marker
13%
Adverse Event
12%
Neutropenia
12%
Cross-Resistance
12%
Non Muscle Invasive Bladder Cancer
11%
Mycobacterium Bovis BCG
11%
Muscle Invasive Bladder Cancer
11%
Prednisone
10%
Prostate Specific Antigen
10%
Placebo
9%
Life Expectancy
7%
Cisplatin
7%
Carcinoma in Situ
7%
Diarrhea
7%
Disease Exacerbation
7%
Phase III Trials
7%
Clinical Study
6%
Clinical Trial
6%
Non Seminomatous Germinoma
6%
Immunotherapy
6%
Tamsulosin
5%
Teratoma
5%
Germ Cell Cancer
5%
SLCO1B1
5%
Neutrophilia
5%
11 Oxotestosterone
5%
Budesonide
5%
CD8 Antigen
5%
Lenvatinib
5%
Medicine and Dentistry
Prostate Cancer
49%
Pembrolizumab
45%
Urothelial Cancer
40%
Overall Survival
35%
Biological Marker
32%
Circulating Tumor Cell
30%
Castration Resistant Prostate Cancer
29%
Transitional Cell Carcinoma
28%
Neoplasm
27%
Testis Cancer
23%
Muscle Invasive Bladder Cancer
23%
Cabazitaxel
20%
Arm
18%
Monotherapy
16%
Aneuploidy
15%
Cell-Free DNA
15%
Post-Hoc Analysis
13%
Progression Free Survival
13%
Liquid Biopsy
12%
Cohort Analysis
12%
Hazard Ratio
12%
Clinical Trial
12%
Colonoscopy
11%
Leukapheresis
11%
Mycobacterium Bovis BCG
11%
Non Muscle Invasive Bladder Cancer
11%
Enzalutamide
11%
Diseases
11%
Androgen Deprivation Therapy
10%
Neoadjuvant Chemotherapy
10%
Docetaxel
10%
Cystectomy
9%
Cisplatin
9%
Abiraterone
9%
Lymphocyte
8%
Neutrophil
8%
Placebo
8%
Metastatic Carcinoma
8%
Screening Test
7%
Disease Exacerbation
7%
Systematic Review
7%
Carcinoma in Situ
7%
Immunotherapy
7%
Cost-Effectiveness Analysis
6%
Quality of Life
6%
Androgen Receptor
6%
Decision Making
6%
Prevalence
6%
Prostate Specific Membrane Antigen
6%
Positron Emission Tomography-Computed Tomography
6%